- Stocks
- Pharma & Healthcare
- Kerala Ayur
Kerala Ayur share price
NSE: KERALAYURPharma & HealthcareDrug Manufacturers - Specialty & Generic
Kerala Ayur at a glance
With a market capitalisation of ₹254 Cr, it ranks 2134th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was −147.0% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹35 Cr (+10.9% year on year) and net profit −₹7 Cr, on a consolidated basis. Promoters held 35.61% of the company as of 30 Jun 2026; 20.35% of promoter shares were pledged.
Key numbers
- Market cap
- ₹254 CrRank 2134 on NSE
- Price to book
- 44.52×FY25
- EPS (TTM)
- −₹14.83to Q4 FY26
- ROE
- −147.0%FY25
- ROCE
- −20.0%FY25
- Debt to equity
- 6.95FY25
- Net profit margin
- −11.6%FY25
- Book value / share
- ₹7.89FY25
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Kerala Ayur quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹29 Cr | ₹32 Cr | ₹31 Cr | ₹31 Cr | ₹29 Cr | ₹35 Cr | ₹33 Cr | ₹35 Cr |
| Revenue YoY | +20.4% | +21.7% | +12.4% | +14.3% | −0.1% | +9.4% | +5.9% | +10.9% |
| Net profit | ₹0 Cr | ₹4 Cr | −₹3 Cr | −₹15 Cr | ₹2 Cr | −₹6 Cr | −₹5 Cr | −₹7 Cr |
| Net profit YoY | — | — | — | −15,470.0% | +341.3% | −274.2% | — | — |
| Net margin | 1.6% | 11.5% | −8.7% | −49.1% | 7.1% | −18.3% | −14.0% | −21.3% |
| EPS | ₹0.33 | ₹0.30 | −₹2.40 | −₹13.68 | ₹1.92 | −₹7.23 | −₹3.69 | −₹5.83 |
Kerala Ayur financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹77 Cr | ₹62 Cr | ₹80 Cr | ₹93 Cr | ₹108 Cr | ₹120 Cr |
| Operating profit | ₹5 Cr | −₹7 Cr | ₹2 Cr | −₹3 Cr | ₹1 Cr | −₹12 Cr |
| Net profit | ₹4 Cr | −₹5 Cr | ₹2 Cr | −₹0 Cr | −₹1 Cr | −₹14 Cr |
| EPS (₹) | ₹4.00 | −₹4.00 | ₹0.00 | −₹1.00 | −₹1.00 | −₹12.00 |
| Cash from operations | ₹5 Cr | ₹7 Cr | −₹1 Cr | ₹10 Cr | ₹2 Cr | ₹5 Cr |
| Total debt | ₹52 Cr | ₹66 Cr | ₹37 Cr | ₹50 Cr | ₹59 Cr | ₹18 Cr |
| Shareholders' equity | ₹8 Cr | ₹3 Cr | ₹6 Cr | ₹6 Cr | ₹32 Cr | ₹9 Cr |
Kerala Ayur shareholding pattern
| Holder | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 21 Mar 2026 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 37.83% | 33.14% | 33.14% | 35.61% | 35.61% | 35.61% |
| Foreign institutions | — | — | 0.22% | 0.17% | 0.17% | 0.17% |
| Domestic institutions | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% |
| Non-institutions | 62.13% | 66.82% | 66.60% | 64.19% | 64.19% | 64.19% |
| Promoter shares pledged | 20.69% | 23.56% | 23.56% | 20.35% | 20.35% | 20.35% |
Kerala Ayur vs peers
The listed Pharma & Healthcare companies nearest to Kerala Ayur by market capitalisation.
Ask anything about Kerala Ayur
Pivot answers on the live chart with evidence you can check, and tests strategies against KERALAYUR's own history. Try: “Why has KERALAYUR moved over the last three months?” · “Backtest a 50-day moving-average crossover on KERALAYUR over five years” · “Compare KERALAYUR with ESPIRE on margins and valuation”
Frequently asked questions about Kerala Ayur
What is the market cap of Kerala Ayur?
Kerala Ayur's market capitalisation is ₹254 Cr (₹254 Cr) at the 22 Oct 2026 close, ranking 2134th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Kerala Ayur?
Return on equity was −147.0% in FY25 and return on capital employed was −20.0% in FY25 (consolidated figures).
Is Kerala Ayur a debt-free company?
No. Kerala Ayur's debt-to-equity ratio was 6.95 in FY25, with total debt of ₹18 Cr.
What were Kerala Ayur's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Kerala Ayur reported revenue of ₹35 Cr, +10.9% year on year, and net profit of −₹7 Cr.
What is the shareholding pattern of Kerala Ayur?
As of 30 Jun 2026: promoters 35.61%, foreign institutions 0.17%, domestic institutions 0.04%, non-institutions 64.19%. 20.35% of promoter shares were pledged.
Who are Kerala Ayur's competitors?
The listed Pharma & Healthcare companies closest to Kerala Ayur by market cap are Espire Hospital, Zenotech Labs, Everest Organic, Gennex Labs, Nath Bio-Genes (India) and BDH Industries.
Is Kerala Ayur a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Kerala Ayur's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on KERALAYUR against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with K · all NSE stocks · this page as text